Stage (next event)
Phase 2 (Interim Data)
Catalyst Info & Data Links
TITLE: Voclosporin in Focal Segmental Glomerulosclerosis (FSGS) - Interim Results Phase 2
ClinicalTrial.gov (NCT03598036): Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis (AURONA™)
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
03-05-2020 Phase 2 Interim Data (Fourth Quarter and Full Year 2019 Financial Results)
05-2020: Corporate Overiew
MECHANISM OF ACTION
Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action. By inhibiting calcineurin, voclosporin blocks IL-2 expression and T-cell mediated immune responses and stabilizes the podocyte in the kidney (see details).
Sparsentan - Retrophin, Inc.
VAR 200 (2-hydroxypropyl-β-cyclodextrin, or HPβCD) - Variant Pharmaceuticals
Selective inhibitor of the chemokine receptor CCR2:
CCX140 - ChemoCentryx, Inc.
Updated by MV
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post